Stryker NASDAQ:SYK Group President James Andrew Pierce disclosed a series of transactions in a Form 4 filed with the Securities and Exchange Commission covering activity on February 2, 2026.
The filing shows Pierce sold 475 shares of Stryker common stock on February 2, 2026, at prices ranging from $368.7534 to $368.92, for aggregate proceeds of $175,214.
In the same filing, Pierce is reported to have exercised stock options to acquire 13,840 shares of Stryker common stock at an exercise price of $96.64 per share, representing a total exercise value of $1,337,497. The document also indicates that 8,432 shares were disposed of at a price of $369.56, producing total proceeds of $3,116,129.
After accounting for these transactions, Pierce directly owns 70,563 shares of Stryker common stock. The filing further lists indirect holdings attributed to related accounts: 712 shares listed as By Son GP, 713 shares listed as By Son AP, and 1,595 shares listed as By 401K.
Separately, Stryker Corporation reported fourth-quarter 2025 results that beat analysts' expectations. The company posted earnings per share of $4.47 versus a consensus forecast of $4.39, and reported revenue of $7.2 billion compared with an anticipated $7.12 billion. Stryker's organic sales growth improved to 11.0% in the quarter, up from 9.5% in the same period a year earlier.
Brokerage responses included Needham raising its price target to $454 while maintaining a Buy rating, and Canaccord Genuity reiterating a Buy rating with a $435 target. BTIG increased its price target to $412 and noted a 10.4% growth rate excluding foreign exchange effects. Citizens reiterated a Market Outperform rating with a $440 price target and highlighted strong performance from the company’s MedSurg and Neurotech businesses. The filing also notes double-digit growth in several segments, including Trauma & Extremities and Vascular.
This combination of insider activity and an earnings beat provides transparency on executive-level stock actions alongside confirmation of company-level performance metrics for the quarter. The SEC Form 4 provides the primary disclosure of the transactions and the filing’s figures above are taken directly from that report and the company’s published quarterly figures.
Note: The details in this article are drawn from the Form 4 filing and Stryker’s fourth-quarter 2025 results as disclosed; the article does not introduce additional information beyond those documents.